


**eMedguides™**  
.com

online and in-print Internet directories in medicine



# Cardiology

**AN INTERNET RESOURCE GUIDE**

**December 2001 – November 2002**

**500 new Web sites, plus more**

**EDITION  
2**

**journals, therapies, and disorders**

Reviews and ratings of over  
1,600 top Web sites.

Categorized listings focus on associations,  
conferences, disorders, hospitals,  
journals, research, and more.

All resources are a click away at  
[www.eMedguides.com](http://www.eMedguides.com).

Consulting Editor

**Stephen C. Achuff, M.D.**

David J. Carver Professor of Medicine  
Division of Cardiovascular Medicine  
The Johns Hopkins  
University School of Medicine



online and in-print Internet directories in medicine

# Cardiology

**AN INTERNET  
RESOURCE GUIDE**

**December 2001 — November 2002**



**Consulting Editor**

Stephen C. Achuff, M.D.

*The David J. Carver Professor of Medicine,  
Division of Cardiovascular Medicine,  
The Johns Hopkins University School of Medicine*

Visit **Cardiology**  
at [www.eMedguides.com](http://www.eMedguides.com)

Access code: **0216**

© 2001 eMedguides.com, Inc.  
eMedguides.com, Inc.  
Princeton, NJ 08540

All rights reserved. No part of this book may be reproduced in any form by any electronic or mechanical means (including photocopying, recording, or information storage and retrieval) without permission in writing from the publisher.

For electronic browsing of this book, see  
<http://www.eMedguides.com/cardiology>

The publisher offers discounts on the eMedguides series of books. For more information, contact:

Sales Department  
eMedguides.com, Inc.  
15 Roszel Road  
Princeton, NJ 08540  
*tel* 800-230-1481 x16  
*fax* 609-520-2023  
*e-mail* [sales@eMedguides.com](mailto:sales@eMedguides.com)  
*web* <http://www.eMedguides.com/books>

This book is set in Avenir, BaseNine, Gill Sans, and Sabon typefaces and was printed and bound in the United States of America.

10 9 8 7 6 5 4 3 2 1

ISBN 0-9676811-5-4

## **Cardiology**

### **AN INTERNET RESOURCE GUIDE**

Stephen C. Achuff, M.D., *Consulting Editor*  
*The David J. Carver Professor of Medicine,*  
*Division of Cardiovascular Medicine,*  
*The Johns Hopkins University School of Medicine*

Karen M. Albert, MLS,  
*Consulting Medical Librarian*  
*Director of Library Services, Fox Chase Cancer Center*

Daniel R. Goldenson, *Publisher*

Alysa M. Wilson, *Editor-in-Chief*

Karen B. Schwartz, *Managing Editor*

Ravpreet S. Syalee, *Production Editor*

Barbara Morrison, *Manuscript Editor*

Joyce Milione, *Production Assistant*

Sue Bannon, *Graphic Designer*

**eMedguides.com, Inc.,**  
**a Thomson Healthcare company**  
15 Roszel Road, Princeton, NJ 08540

Daniel R. Goldenson  
*General Manager*

Amy Ma, Ph.D.,  
*Coordinator, Publication Development*

Kim Seok,  
*Coordinator, Finance Administration*

### **Book Orders & Feedback**

Book orders • <http://www.eMedguides.com/books>

Phone orders • 800.230.1481 x16

Facsimile • 609.520.2023

E-mail • [cardiology@eMedguides.com](mailto:cardiology@eMedguides.com)

Web • <http://www.eMedguides.com/cardiology>

## **2001–2002 Annual Editions**

Allergy & Immunology  
Anesthesiology & Pain Management  
Arthritis & Rheumatology

### **Cardiology**

Dental Medicine  
Dermatology  
Diet & Nutrition  
Emergency Medicine  
Endocrinology & Metabolism  
Family Medicine  
Gastroenterology  
General Surgery  
Infectious Diseases & Immunology  
Internal Medicine  
Neurology & Neuroscience  
Nurse Practitioners  
Obstetrics & Gynecology  
Oncology & Hematology  
Ophthalmology  
Orthopedics & Sports Medicine  
Osteopathic Medicine  
Otolaryngology  
Pathology & Laboratory Medicine  
Pediatrics & Neonatology  
Physical Medicine & Rehabilitation  
Psychiatry  
Radiology  
Respiratory & Pulmonary Medicine  
Urology & Nephrology  
Veterinary Medicine

## Disclaimer

eMedguides.com, Inc., hereafter referred to as the “publisher,” has developed this book for informational purposes only, and not as a source of medical advice. The publisher does not guarantee the accuracy, adequacy, timeliness, or completeness of any information in this book and is not responsible for any errors or omissions or any consequences arising from the use of the information contained in this book. The material provided is general in nature and is in summary form. The content of this book is not intended in any way to be a substitute for professional medical advice. One should always seek the advice of a physician or other qualified healthcare provider. Further, one should never disregard medical advice or delay in seeking it because of information found through an Internet Web site included in this book. The use of the eMedguides.com, Inc. book is at the reader’s own risk.

All information contained in this book is subject to change. Mention of a specific product, company, organization, Web site URL address, treatment, therapy, or any other topic does not imply a recommendation or endorsement by the publisher.

### *Non-liability*

The publisher does not assume any liability for the contents of this book or the contents of any material provided at the Internet sites, companies, and organizations reviewed in this book. Moreover, the publisher assumes no liability or responsibility for damage or injury to persons or property arising from the publication and use of this book; the use of those products, services,

information, ideas, or instructions contained in the material provided at the third-party Internet Web sites, companies, and organizations listed in this book; or any loss of profit or commercial damage including but not limited to special, incidental, consequential, or any other damages in connection with or arising out of the publication and use of this book. Use of third-party Web sites is subject to the Terms and Conditions of use for such sites.

### *Copyright Protection*

Information available over the Internet and other online locations may be subject to copyright and other rights owned by third parties. Online availability of text and images does not imply that they may be reused without the permission of rights holders. Care should be taken to ensure that all necessary rights are cleared prior to reusing material distributed over the Internet and other online locations.

### *Trademark Protection*

The words in this book for which we have reason to believe trademark, service mark, or other proprietary rights may exist have been designated as such by use of initial capitalization. However, no attempt has been made to designate as trademarks or service marks all personal computer words or terms in which proprietary rights might exist. The inclusion, exclusion, or definition of a word or term is not intended to affect, or to express any judgment on, the validity or legal status of any proprietary right that may be claimed in that word or term.



# EMEDGUIDES.COM ONLINE

Instant access to every Web site in this book at [www.eMedguides.com](http://www.eMedguides.com)!

This volume, *in its entirety*, can be browsed online at [eMedguides.com](http://eMedguides.com). Simply point and click to surf to the latest Web sites in your specialty! [eMedguides.com](http://eMedguides.com) is continually updated

with URL and content changes, as well as new sites in each specialty. Start your search for medical information, in any specialty, with the trusted assistance of [eMedguides.com](http://eMedguides.com).

## THREE WAYS TO SURF WITH AN EMEDGUIDE:

**FAST** Drill down at [eMedguides.com](http://eMedguides.com) to the Web information you seek.

**FASTER** Find a site in the print edition and type the URL into your browser.

**FASTEST** Find a site in the print edition and type in the e-Link code instead of the URL (for example, go to site G-1234 by typing: [www.eMedguides.com/G-1234](http://www.eMedguides.com/G-1234)).

### GENERAL MEDICINE REFERENCE

Part Two of every book (General Medical Web Resources) is always available in the sidebar.

### E-LINK WITH THE URL

Type in the e-Link code (found next to each entry in this book) after [www.eMedguides.com/](http://www.eMedguides.com/). You will go directly to the site you seek, even if the URL has changed.

### TELL US ABOUT A SITE

When you find a terrific site, tell us about it. Fill out a simple form and we may add your site immediately to [eMedguides.com](http://eMedguides.com), and we may include it in our next print edition too.

### BUY MORE BOOKS

Quickly order books in any of our available specialties, including patient guides, from our online store.

### FREE JOURNALS & ASSOCIATIONS

Hundreds of links to journals and associations in each of over 20 specialties are provided.

### BROWSE THE TABLE OF CONTENTS

You can quickly find every topic using the full table of contents.

### FULL PRINT EDITION, ONLINE

Click to view the sites in a topic. An access code is required; you can find it on the title page of this book.


### E-LINK OR SEARCH

Enter an e-Link code (found next to each site in this book) or enter a text string to search the entire specialty.

The screenshot shows the eMedguides.com website in a web browser. The browser's address bar displays <http://www.eMedguides.com>. The website has a green and blue color scheme. At the top, it says "eMedguides.com" and "Online and in-print Internet directories in medicine". Below this, there are navigation links: "GENERAL MEDICINE GUIDE" (with "no code required" below it), "about us", "submit site", "feedback", and "order books". On the left sidebar, there are several categories: "REFERENCE" (with sub-links: acronyms, conferences, fed. gov't agencies, full-text articles, glossaries, gov't databases, health insurance, hospitals, hotlines, journal search, journals, legislation, libraries, MD background, MD locator, medical databases), "FREE JOURNALS & ASSOCIATIONS", "BROWSE THE TABLE OF CONTENTS", "FULL PRINT EDITION, ONLINE", and "E-LINK OR SEARCH". The main content area has a "WELCOME TO CARDIOLOGY" header. Below this, there are two columns. The left column lists "Specialty Overview" with links: "Supersites", "Cardiology", "General Resources", "National Heart, Lung, and Blood Institute (NHLBI)", and "Comprehensive Profile". The right column has a "No login required:" section with links for "Journals" and "Associations". Below this is a search box with the text "Enter e-Link: G-6234" and "or Search". There is a dropdown menu set to "All" and a "go" button. On the far right, there is a "CONSULTING EDITOR" section listing "Stephen C. Achuff, M.D." and "David J. Carver Professor of Medicine, Division of Cardiovascular Medicine, The Johns Hopkins University School of Medicine". At the bottom right, there is a "Biological, Diagnostic, and Therapeutic Aspects" section with links: "Anatomy and Physiology", "Risk Factors, Causes, and Prevention", and "Symptoms".

# PRAVACHOL<sup>®</sup>

pravastatin sodium 40 mg tablets



Please see full prescribing information  
in appendix A at the end of this book.

New NCEP\* guidelines† identify  
more patients than ever in the **CV RISK ZONE**

Help bring your patients to the

# PRAVACHOL PROTECTION ZONE:

Aggressive cardioprotection. Proven safety.



**Now the CV Risk Zone includes patients with†:**

**Borderline-high LDL-C  
(LDL-C 130-159 mg/dL)**

**2+ risk factors**

**≥10% ten-year risk for  
major CHD events**

**Diabetes — now a  
CHD risk equivalent**

**LDL-C ≥100 mg/dL**

**>20% ten-year risk for  
major CHD events**

\* NCEP = National Cholesterol Education Program

† Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adults Treatment Panel III). JAMA. 2001;285:2486-2497.



# PRAVACHOL lowers CV risk — NOW with reduced recommendations for LFT monitoring\*

New LFT labeling—  
No recommended  
12-week follow-up

## Aggressive cardioprotection

In addition to diet, when diet and exercise are not enough in patients with elevated cholesterol or CHD


- PRAVACHOL is the only statin proven to reduce the risk of both first and recurrent MI, as well as stroke<sup>1,4</sup>
- Reduce the risk of total mortality by reducing coronary death<sup>1,4</sup>

## \* Proven safety

- It is recommended that liver function tests be performed prior to initiating therapy, prior to increasing the dose, and when otherwise clinically indicated
- If a patient develops increased transaminase levels, or signs and symptoms of liver disease, more frequent monitoring may be required
- Reduced potential for CYP450 3A4 drug interactions

## Important Safety Information:

- Pravachol is contraindicated for patients who are pregnant or nursing and in the presence of active liver disease or unexplained persistent transaminase elevations.
- Myopathy should be considered in any patient with diffuse myalgias, muscle tenderness or weakness, and/or marked elevation of creatine phosphokinase (CPK). Patients should be advised to report promptly unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. The risk of myopathy during treatment with another HMG-CoA reductase inhibitor is increased with concurrent therapy with erythromycin, cyclosporin, niacin or fibrates. The combined use of Pravachol and fibrates should be avoided unless the benefit of further alterations in lipid levels is likely to outweigh the increased risk of this drug combination.
- Pravachol is well tolerated. The most common adverse events are rash, fatigue, headache, and dizziness.

- 
1. Pravachol product labeling, Bristol-Myers Squibb Company.
  2. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. *N Engl J Med.* 1995;333:1301-1307.
  3. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. *N Engl J Med.* 1996;335:1001-1007.
  4. The Long-Term intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. *N Engl J Med.* 1998;339:1349-1357

Please see full prescribing information in appendix A at the end of this book.

**PRAVACHOL<sup>®</sup>**  
pravastatin sodium 40 mg tablets  
Help Put Your Patients in the Protection Zone

New NCEP\* guidelines† identify  
more patients than ever in the **CV RISK ZONE**

Help bring your patients to the

# PRAVACHOL PROTECTION ZONE:

Aggressive cardioprotection. Proven safety.



Now the CV Risk Zone includes patients with†:

**Borderline-high LDL-C**  
**(LDL-C 130-159 mg/dL)**

**2+ risk factors**

**≥10% ten-year risk for**  
**major CHD events**

**Diabetes — now a**  
**CHD risk equivalent**

**LDL-C ≥100 mg/dL**

**>20% ten-year risk for**  
**major CHD events**

\* NCEP = National Cholesterol Education Program

† Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adults Treatment Panel III). *JAMA*. 2001;285:2486-2497.



# PRAVACHOL lowers CV risk — NOW with reduced recommendations for LFT monitoring\*

New LFT labeling—  
No recommended  
12-week follow-up

## Aggressive cardioprotection

In addition to diet, when diet and exercise are not enough in patients with elevated cholesterol or CHD


- PRAVACHOL is the only statin proven to reduce the risk of both first and recurrent MI, as well as stroke<sup>1-4</sup>
- Reduce the risk of total mortality by reducing coronary death<sup>1,4</sup>

## \* Proven safety

- It is recommended that liver function tests be performed prior to initiating therapy, prior to increasing the dose, and when otherwise clinically indicated
- If a patient develops increased transaminase levels, or signs and symptoms of liver disease, more frequent monitoring may be required
- Reduced potential for CYP450 3A4 drug interactions

## Important Safety Information:

- Pravachol is contraindicated for patients who are pregnant or nursing and in the presence of active liver disease or unexplained persistent transaminase elevations.
- Myopathy should be considered in any patient with diffuse myalgias, muscle tenderness or weakness, and/or marked elevation of creatine phosphokinase (CPK). Patients should be advised to report promptly unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. The risk of myopathy during treatment with another HMG-CoA reductase inhibitor is increased with concurrent therapy with erythromycin, cyclosporin, niacin or fibrates. The combined use of Pravachol and fibrates should be avoided unless the benefit of further alterations in lipid levels is likely to outweigh the increased risk of this drug combination.
- Pravachol is well tolerated. The most common adverse events are rash, fatigue, headache, and dizziness.

- 
1. Pravachol product labeling, Bristol-Myers Squibb Company.
  2. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. *N Engl J Med*. 1995;333:1301-1307.
  3. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. *N Engl J Med*. 1996;335:1001-1007.
  4. The Long-Term intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. *N Eng J Med*. 1998;339:1349-1357

Please see full prescribing information in appendix A at the end of this book.

**PRAVACHOL<sup>®</sup>**  
pravastatin sodium 40 mg tablets  
Help Put Your Patients in the Protection Zone

## TABLE OF CONTENTS

<b>Preface . . . . .</b>	<b>1</b>	<b>5. CARDIOLOGY OVERVIEW SITES . 67</b>
<b>1. INTRODUCTION . . . . .</b>	<b>3</b>	5.1 Supersites . . . . . 67
1.1 Welcome to eMedguides . . . . .	3	5.2 General Resources for Cardiology . 71
1.2 Ratings and Site Selection . . . . .	5	5.3 Awards and Honors. . . . . 73
1.3 Getting Online . . . . .	6	<i>Awards for Service. . . . . 73</i>
<b>PART ONE Cardiology</b>		<i>Investigator and Research Awards . 73</i>
<b>Web Resources</b>		<i>Scholarship Awards . . . . . 77</i>
<b>2. QUICK REFERENCE. . . . .</b>	<b>13</b>	5.4 National Heart, Lung, and
2.1 Disorder Profiles . . . . .	13	Blood Institute (NHLBI) Profile. . . 78
2.2 Glossaries . . . . .	14	<i>Departments and Services . . . . . 78</i>
2.3 Conferences in Cardiology . . . . .	14	<i>Extramural</i>
2.4 Topical Search Tools . . . . .	15	<i>Funding Opportunities . . . . . 79</i>
2.5 Cardiology News. . . . .	16	<i>Research . . . . . 79</i>
2.6 Statistics . . . . .	18	<b>6. BIOLOGICAL, DIAGNOSTIC,</b>
2.7 Clinical Studies and Trials. . . . .	19	<b>AND THERAPEUTIC ASPECTS. . . 81</b>
2.8 Drug Pipeline: Approved and		6.1 Anatomy and Physiology. . . . . 81
Developmental Drugs . . . . .	20	<i>General Resources . . . . . 81</i>
2.9 Online Texts and Tutorials . . . . .	20	<i>Cardiovascular Embryology. . . . . 82</i>
<b>3. JOURNALS, ARTICLES,</b>		<i>The Heart . . . . . 83</i>
<b>AND LATEST BOOKS . . . . .</b>	<b>23</b>	<i>Conduction System . . . . . 83</i>
3.1 Abstract, Citation,		<i>Cardiac Cycle . . . . . 84</i>
and Full-Text Search Tools . . . . .	23	<i>Electrophysiology . . . . . 84</i>
3.2 Articles and Reviews . . . . .	24	<i>The Blood . . . . . 85</i>
3.3 Journals on		<i>The Circulation . . . . . 86</i>
the Internet: Cardiology . . . . .	24	<i>Blood Flow and Pressure . . . . . 86</i>
3.4 Books on Cardiology		<i>Arterial System . . . . . 87</i>
Published in 2000/2001 . . . . .	38	<i>Venous System. . . . . 87</i>
<b>4. CONTINUING MEDICAL</b>		<i>Lymphatics . . . . . 88</i>
<b>EDUCATION (CME). . . . .</b>	<b>59</b>	<i>Control of</i>
4.1 CME Resources: Cardiology . . . . .	59	<i>Cardiovascular Function . . . . . 88</i>
4.2 CME Resources. . . . .	60	6.2 Risk Factors and Causes . . . . . 89
4.3 Selected Medical		<i>General Resources . . . . . 89</i>
School CME Programs . . . . .	62	<i>Age . . . . . 90</i>
		<i>Atherosclerosis . . . . . 90</i>
		<i>Baldness . . . . . 91</i>
		<i>C-Reactive Protein. . . . . 91</i>
		<i>Coagulation Factors . . . . . 91</i>
		<i>Culture, Race, and Ethnicity . . . . . 92</i>
		<i>Diabetes . . . . . 92</i>
		<i>Gender-Specific Risk Factors . . . . . 93</i>
		<i>Genetics . . . . . 94</i>



	Homocysteine . . . . .	94		Assessment of	
	Hypercholesterolemia . . . . .	94		Functional Capacity . . . . .	114
	Hyperinsulinemia . . . . .	95		Auscultation . . . . .	114
	Hypertension . . . . .	95		Blood Pressure . . . . .	115
	Hypomagnesemia . . . . .	96		Body Composition Tests . . . . .	116
	Lipoprotein (a) . . . . .	96		C-Reactive Protein Screening . . . . .	116
	Obesity and Overweight . . . . .	96		Calcium . . . . .	116
	Physical Inactivity/Sedentarism . . . . .	97		Cardiac Catheterization . . . . .	116
	Phytochemicals . . . . .	97		Cardiac Glycosides . . . . .	117
	Sex Hormones . . . . .	98		Cardiac Imaging, General . . . . .	117
	Smoking . . . . .	98		Cardiotocography . . . . .	117
	Stress . . . . .	99		Computed	
	Substance Abuse . . . . .	99		Tomography (CT Scan) . . . . .	118
	Triglycerides/Trans Fatty Acids . . . . .	99		Contrast Echocardiography . . . . .	118
6.3	Screening and Prevention . . . . .	100		Coronary Calcification Scoring . . . . .	119
	General Resources . . . . .	100		Echocardiography . . . . .	119
	Alcohol and Heart Disease . . . . .	102		Electro-mapping . . . . .	120
	Antioxidant Consumption . . . . .	102		Electrocardiography . . . . .	120
	Aspirin . . . . .	103		Electrophysiology Studies . . . . .	121
	Blood Pressure Screening . . . . .	103		Event Recording/	
	Cholesterol Screening			Transtelephonic ECG . . . . .	121
	and Reduction . . . . .	103		Exercise Stress Testing . . . . .	121
	Dietary Intervention . . . . .	104		Fetal Cardiology Imaging . . . . .	122
	Exercise/Physical Activity . . . . .	105		HIS-Bundle Electrography . . . . .	123
	Gender-Specific Risk			Holter Monitoring/Ambulatory	
	Factor Management . . . . .	106		Electrocardiography . . . . .	123
	Smoking Cessation . . . . .	107		Lipid-Level Profile Testing . . . . .	123
6.4	Signs and Symptoms . . . . .	107		Lumbar Puncture . . . . .	124
	General Resources . . . . .	107		Magnetic Resonance	
	Bradycardia . . . . .	108		Angiography (MRA) . . . . .	125
	Carotid Bruit . . . . .	108		Magnetic Resonance	
	Chest Pain/Angina . . . . .	108		Imaging (MRI) . . . . .	125
	Claudication . . . . .	109		Myocardial Biopsy . . . . .	126
	Cyanosis . . . . .	109		Myocardial Infarction Scan . . . . .	126
	Dyspnea . . . . .	109		Nuclear Imaging/Myocardial	
	Fatigue . . . . .	110		Perfusion, General . . . . .	127
	Gender-Specific Symptoms . . . . .	110		Nuclear Imaging:	
	Murmurs . . . . .	110		Exercise Stress Test . . . . .	127
	Palpitations . . . . .	111		Nuclear Imaging: Gated	
	Syncope . . . . .	111		Blood Pool Scan (MUGA) . . . . .	128
6.5	Diagnostics . . . . .	112		Nuclear Imaging:	
	General Resources . . . . .	112		Pharmacologic Stress Test . . . . .	129
	Angiography, General . . . . .	112		Pericardiocentesis . . . . .	129
	Apexcardiography . . . . .	113		Pharmacologic Stress	
	Arteriography . . . . .	113		Echocardiography . . . . .	129

	Phonocardiography . . . . .	130		Magnesium Therapy . . . . .	150
	Positron Emission			Myocardial Infarction	
	Tomography (PET) Scan . . . . .	130		Therapy, General . . . . .	151
	Potassium . . . . .	131		Nitrates . . . . .	151
	Radiography . . . . .	131		Potassium . . . . .	152
	Serum Cardiac Markers, General .	131		Sympatholytics, General . . . . .	152
	Signal-Averaged			Thrombolytic Therapy . . . . .	152
	Electrocardiogram . . . . .	132		Vasodilators, General . . . . .	153
	Single Photon Emission Computed		6.8	Procedures/Therapies . . . . .	153
	Tomography (SPECT) . . . . .	132		General Resources . . . . .	153
	Stroke Tests . . . . .	133		Aortic Valve Surgery . . . . .	155
	Tilt Table Test (TTT) . . . . .	133		Arterial Catheterization . . . . .	155
	Transesophageal			Arterial Grafts . . . . .	156
	Echocardiogram (TEE) . . . . .	133		Arterial Switch . . . . .	156
	Ventriculography . . . . .	134		Atherectomy . . . . .	156
6.6	Pathology and Case Studies . . . .	135		Atrial Switch . . . . .	157
6.7	Pharmacology . . . . .	138		Balloon Angioplasty/	
	General Resources . . . . .	138		Percutaneous Transluminal	
	Aldosterone Antagonists			Coronary Angioplasty (PTCA) .	157
	(Spironolactone) . . . . .	140		Balloon Atrial Septostomy . . . . .	158
	Alpha Blockers . . . . .	140		Blalock-Taussig Shunt . . . . .	158
	Angiotensin Converting			Cardiac Catheterization . . . . .	159
	Enzyme (ACE) Inhibitors . . . . .	140		Cardiac Pacemaker/	
	Angiotensin II Inhibitors . . . . .	141		Implantable Antiarrhythmic	
	Antianginal Agents, General . . .	141		Devices, General . . . . .	159
	Antiarrhythmic Agents, General .	142		Cardiomyoplasty . . . . .	161
	Anticoagulants . . . . .	143		Cardiopulmonary	
	Antihypertensives, General . . . .	143		Resuscitation (CPR) . . . . .	161
	Antiplatelet Agents/Aspirin . . . .	144		Cardioversion . . . . .	162
	Antithrombotic Agents, General .	145		Carotid Endarterectomy . . . . .	163
	Beta Blockers . . . . .	145		Catheter Ablation . . . . .	163
	Calcium Channel Blockers . . . . .	145		Central Venous Catheterization . .	165
	Centrally Acting Agents			Coil Closure of Patent Ductus	
	(Antihypertensives) . . . . .	146		Arteriosus . . . . .	165
	Chelation Therapy . . . . .	146		Congenital Heart	
	Coenzyme Q10 . . . . .	146		Disease Treatments, General . . .	165
	Congestive Heart			Coronary Artery	
	Failure Drugs, General . . . . .	147		Bypass Grafting (CABG) . . . . .	166
	Digoxin/Cardiac Glycosides . . . .	147		Damus-Kaye-Stansel Operation . .	167
	Diuretics, General . . . . .	148		Endoscopic Vein Harvesting . . . .	167
	Folic Acid . . . . .	148		Endovascular Graft . . . . .	167
	Hormone Replacement Therapy/			Enhanced External	
	Estrogen Replacement Therapy .	149		Counterpulsation (EECP) . . . . .	168
	Inotropic Drugs, General . . . . .	150		Fontan Procedure . . . . .	168
	Lipid Lowering Agents . . . . .	150		Gene Therapy . . . . .	169

<i>Interventional Radiology</i> . . . . .	169	<i>Valvuloplasty</i> . . . . .	180
<i>Intracoronary Artery Radiation</i> . .	170	<i>Ventricle-and-a-Half Repairs</i> . . .	181
<i>Left Ventricular</i>		6.9 <i>Transplantation</i> . . . . .	181
<i>Assist Devices (LVAD)</i> . . . . .	170	6.10 <i>Cardiac Rehabilitation</i> . . . . .	184
<i>Left Ventricular</i>		6.11 <i>Clinical Practice Guidelines</i>	
<i>Reduction/Batista Procedure</i> . .	170	<i>and Disease Management</i> . . . . .	186
<i>Maze Procedure</i> . . . . .	170		
<i>Minimally Invasive</i>		<b>7. OTHER TOPICAL RESOURCES . . 189</b>	
<i>Direct Coronary Artery</i>		7.1 <i>Advocacy and Public Policy</i> . . . .	189
<i>Bypass (MIDCAB)</i> . . . . .	171	7.2 <i>Air Pollution</i> . . . . .	190
<i>Minimally Invasive</i>		7.3 <i>Anesthesiology</i> . . . . .	190
<i>Heart Surgery, General</i> . . . . .	171	7.4 <i>Artificial Hearts</i> . . . . .	191
<i>Mitral Valve Surgery</i> . . . . .	172	7.5 <i>Autoimmunity</i> . . . . .	191
<i>Norwood Operation</i> . . . . .	173	7.6 <i>Computers in Cardiology</i> . . . . .	192
<i>Off-Pump Coronary</i>		7.7 <i>Critical Care Medicine</i> . . . . .	193
<i>Artery Bypass (OPCAB)</i> . . . . .	173	7.8 <i>Drug Abuse</i> . . . . .	194
<i>Percutaneous Balloon</i>		7.9 <i>Epidemiology and Biostatistics</i> . .	195
<i>Commissurotomy</i> . . . . .	173	7.10 <i>Extracorporeal</i>	
<i>Percutaneous Coronary</i>		<i>Technology/Life Support</i> . . . . .	195
<i>Intervention, General</i> . . . . .	174	7.11 <i>Fetal/Neonatal Cardiology</i> . . . . .	196
<i>Perfusion</i> . . . . .	174	7.12 <i>Genetics and Genomics</i> . . . . .	197
<i>Peripherally Inserted</i>		7.13 <i>Geriatric Cardiology</i> . . . . .	198
<i>Central Catheter (PICC)</i> . . . . .	175	7.14 <i>Heart Studies</i> . . . . .	198
<i>Port Access Coronary Artery</i>		7.15 <i>History of Cardiology</i> . . . . .	204
<i>Bypass (PortCAB/PACAB)</i> . . . .	175	7.16 <i>Medical Informatics</i> . . . . .	204
<i>Preventive Therapy</i> . . . . .	175	7.17 <i>Nuclear Cardiology</i> . . . . .	205
<i>Pulmonary Artery Banding</i> . . . .	176	7.18 <i>Nutrition</i> . . . . .	206
<i>Pulmonary Artery</i>		7.19 <i>Patient Education and Support</i> . .	208
<i>Catheterization</i> . . . . .	176	7.20 <i>Pediatric Cardiology</i> . . . . .	211
<i>Repair of Double</i>		7.21 <i>Radiology/Imaging</i> . . . . .	214
<i>Outlet Right Ventricle</i> . . . . .	176	7.22 <i>Sexual Activity</i>	
<i>Repair of Interrupted</i>		<i>and Heart Disease</i> . . . . .	216
<i>Aortic Arch</i> . . . . .	177	7.23 <i>Transfusion Medicine</i> . . . . .	216
<i>Repair of Tetralogy of Fallot</i> . . .	177	7.24 <i>Vascular Medicine</i> . . . . .	217
<i>Repair of Truncus Arteriosus</i> . .	177	7.25 <i>Women's Cardiac Health</i> . . . . .	219
<i>Reperfusion Therapy</i> . . . . .	177		
<i>Ross Procedure</i> . . . . .	178	<b>8. ORGANIZATIONS</b>	
<i>Stent Implantation</i> . . . . .	178	<b>AND INSTITUTIONS . . . . . 221</b>	
<i>Superior Cavopulmonary</i>		8.1 <i>Associations and Societies</i> . . . . .	221
<i>Anastomosis (BDG Shunt)</i> . . . .	179		
<i>Transmyocardial Laser</i>			
<i>Revascularization (TMR)</i> . . . .	179		
<i>Valve Replacement</i>			
<i>Surgery, General</i> . . . . .	180		
<i>Valvotomy</i> . . . . .	180		

8.2	Cardiology Departments at Medical Schools and Hospitals . . .	238			
8.3	Foundations and Grant Support. . . . .	255			
8.4	Selected Research Centers . . . . .	257			
	<i>Clinical Research</i>				
	<i>Centers and Services</i> . . . . .	257			
	<i>Selected Research</i>				
	<i>Center Web Sites</i> . . . . .	257			
<b>9.</b>	<b>DISEASES/DISORDERS . . . . .</b>	<b>263</b>			
9.1	Adams-Stokes Disease . . . . .	263			
9.2	Arrhythmias/ Dysrhythmias. . . . .	263			
	<i>General Resources</i> . . . . .	263			
	<i>Accelerated</i>				
	<i>Idioventricular Rhythm</i> . . . . .	265			
	<i>Atrial Fibrillation</i> . . . . .	265			
	<i>Atrial Flutter</i> . . . . .	265			
	<i>Bradycardias</i> . . . . .	266			
	<i>Ectopic Beats</i> . . . . .	267			
	<i>Junctional Rhythm</i> . . . . .	267			
	<i>Multifocal Atrial Tachycardia</i> . . .	267			
	<i>Narrow-QRS Tachycardias</i>				
	<i>with Regular Rhythm</i> . . . . .	268			
	<i>Supraventricular Tachycardias</i> . . .	268			
	<i>Tachycardias, General</i> . . . . .	269			
	<i>Torsade de Pointes</i> . . . . .	269			
	<i>Ventricular</i>				
	<i>Tachycardias, General</i> . . . . .	270			
	<i>Wide-Complex Tachycardia</i> . . . .	271			
9.3	Arteriosclerosis . . . . .	271			
	<i>General Resources</i> . . . . .	271			
	<i>Atherosclerosis</i> . . . . .	272			
	<i>Nonatheromatous</i>				
	<i>Arteriosclerosis</i> . . . . .	273			
9.4	Cardiac Arrest . . . . .	273			
	<i>General Resources</i> . . . . .	273			
	<i>Asystole</i> . . . . .	274			
	<i>Pulseless Electrical Activity</i> . . . .	274			
	<i>Ventricular Fibrillation/ Pulseless</i>				
	<i>Ventricular Tachycardia</i> . . . . .	274			
9.5	Cardiac Infectious Diseases . . . . .	275			
	<i>General Resources</i> . . . . .	275			
	<i>Chagas' Disease</i> . . . . .	275			
	<i>Chlamydia pneumoniae</i>				
	<i>and Cardiovascular Disease</i> . . . .	275			
	<i>Infective Endocarditis</i> . . . . .	276			
	<i>Myocarditis, General</i> . . . . .	277			
	<i>Myocarditis, Viral</i> . . . . .	277			
	<i>Pericarditis, Acute</i> . . . . .	278			
	<i>Pericarditis, Viral</i> . . . . .	278			
	<i>Postpericardiotomy Syndrome</i> . . .	278			
	<i>Rheumatic Fever</i> . . . . .	279			
9.6	Cardiac Tumors. . . . .	279			
	<i>General Resources</i> . . . . .	279			
	<i>Cardiac Angiosarcoma</i> . . . . .	280			
	<i>Cardiac Fibroma</i> . . . . .	280			
	<i>Cardiac Sarcoma, General</i> . . . . .	280			
	<i>Carney Complex</i> . . . . .	281			
	<i>Cysts</i> . . . . .	281			
	<i>Lipoma</i> . . . . .	281			
	<i>Myxoma</i> . . . . .	281			
	<i>Rhabdomyoma</i> . . . . .	282			
	<i>Rhabdomyosarcoma</i> . . . . .	282			
9.7	Cardiovascular Shock . . . . .	283			
	<i>General Resources</i> . . . . .	283			
	<i>Acute Adrenal Insufficiency</i> . . . .	283			
	<i>Anaphylactic Shock</i> . . . . .	283			
	<i>Cardiogenic Shock</i> . . . . .	284			
	<i>Drug-Induced Shock</i> . . . . .	284			
	<i>Hypovolemic Shock</i> . . . . .	284			
	<i>Obstructive Shock, General</i> . . . .	285			
	<i>Pulmonary Embolism</i> . . . . .	285			
	<i>Septic Shock</i> . . . . .	285			
	<i>Tension Pneumothorax</i> . . . . .	286			
	<i>Vasodilatory Shock</i> . . . . .	286			
9.8	Cerebrovascular Disease . . . . .	286			
	<i>General Resources</i> . . . . .	286			
	<i>Arteriovenous</i>				
	<i>Malformations (AVM)</i> . . . . .	287			
	<i>Central Nervous</i>				
	<i>System Vasculitis</i> . . . . .	287			
	<i>Hemorrhagic</i>				
	<i>Syndromes, General</i> . . . . .	287			
	<i>Hemorrhagic Syndromes,</i>				
	<i>Epidural Hematoma</i> . . . . .	288			
	<i>Hemorrhagic Syndromes,</i>				
	<i>Intracerebral Hemorrhage</i> . . . .	288			



	<i>Hemorrhagic Syndromes,</i> <i>Subarachnoid Hemorrhage</i> . . . .	289		<i>Eisenmenger Syndrome</i> . . . . .	305
	<i>Hemorrhagic Syndromes,</i> <i>Subdural Hematoma</i> . . . . .	289		<i>Holt-Oram Syndrome</i> . . . . .	305
	<i>Ischemic Syndromes.</i> . . . .	290		<i>Hypoplastic Left</i> <i>Heart Syndrome (HLHS).</i> . . . .	305
	<i>Moya-Moya Disease</i> . . . . .	292		<i>Ivemark Syndrome (Asplenia)</i> . . .	306
	<i>Vascular</i> <i>Malformations, General</i> . . . . .	292		<i>Long QT Syndrome (LQTS)</i> . . . .	306
	<i>Wallenberg's Syndrome</i> . . . . .	292		<i>Mitral Stenosis,</i> <i>Supravalvular Ring</i> . . . . .	307
9.9	<i>Conduction Disorders</i> . . . . .	293		<i>Noonan Syndrome.</i> . . . .	307
	<i>Atrioventricular Block</i> . . . . .	293		<i>Partial Anomalous</i> <i>Pulmonary Venous Return.</i> . . . .	307
	<i>Bundle Branch Block</i> . . . . .	293		<i>Patent Ductus Arteriosus</i> . . . . .	308
	<i>Hemiblock (Fascicular Block)</i> . . .	294		<i>Pulmonary Atresia.</i> . . . .	309
	<i>His Bundle Arrhythmias</i> . . . . .	294		<i>Pulmonary Stenosis</i> . . . . .	309
	<i>Wolff-Parkinson-</i> <i>White Syndrome</i> . . . . .	294		<i>Septal Defects, General</i> . . . . .	310
9.10	<i>Congenital Heart</i> <i>Disease (CHD)</i> . . . . .	295		<i>Single Ventricle</i> <i>Anomalies, General</i> . . . . .	310
	<i>General Resources</i> . . . . .	295		<i>Sinus of Valsalva Aneurysm.</i> . . . .	311
	<i>Absence of the</i> <i>Left Pericardium</i> . . . . .	298		<i>Subaortic Stenosis</i> . . . . .	311
	<i>Aortic Stenosis.</i> . . . .	298		<i>Tetralogy of Fallot.</i> . . . .	311
	<i>Arrhythmogenic Right</i> <i>Ventricular Dysplasia (ARVD).</i> . .	299		<i>Total Anomalous Pulmonary</i> <i>Venous (P-V) Connection</i> . . . .	312
	<i>Atrial Septal Defect</i> . . . . .	299		<i>Transposition of</i> <i>the Great Arteries</i> . . . . .	312
	<i>Atrioventricular (A-V)</i> <i>Canal Defect</i> . . . . .	300		<i>Tricuspid Atresia</i> . . . . .	313
	<i>Barth Syndrome</i> <i>(X-Linked Cardiomyopathy)</i> . . .	300		<i>Truncus Arteriosus</i> . . . . .	313
	<i>Bicuspid Aortic Valve.</i> . . . .	301		<i>Turner's Syndrome</i> . . . . .	314
	<i>Cardio-Facio-</i> <i>Cutaneous (CFC) Syndrome</i> . . .	301		<i>Velo-Cardio-Facial Syndrome</i> <i>(Cayler Syndrome,</i> <i>DiGeorge Syndrome).</i> . . . .	314
	<i>CHARGE Syndrome</i> . . . . .	301		<i>Ventricular Septal Defect (VSD).</i> . .	314
	<i>Coarctation of the Aorta.</i> . . . .	301		<i>Williams Syndrome (Supra-aortic</i> <i>Stenosis/Pulmonary Stenosis).</i> . .	315
	<i>Congenital Heart Block</i> . . . . .	302	9.11	<i>Connective Tissue Disease</i> . . . . .	315
	<i>Cor Triatriatum.</i> . . . .	302		<i>Kawasaki Syndrome</i> . . . . .	315
	<i>Coronary Artery</i> <i>Anomalies, General</i> . . . . .	303		<i>Marfan Syndrome</i> . . . . .	316
	<i>Double Aortic Arch</i> . . . . .	303		<i>Polyarteritis Nodosa</i> . . . . .	317
	<i>Double Outlet Right Ventricle</i> . . .	303		<i>Systemic Lupus Erythematosus</i> . .	317
	<i>Double-Chambered</i> <i>Right Ventricle</i> . . . . .	304		<i>Takayasu's Arteritis</i> . . . . .	318
	<i>Down Syndrome and</i> <i>Congenital Heart Defects</i> . . . .	304		<i>Temporal Arteritis</i> <i>(Giant Cell Arteritis).</i> . . . .	318
	<i>Ebstein's Anomaly</i> . . . . .	304		<i>Vasculitis, General Resources</i> . . .	319
			9.12	<i>Coronary</i> <i>Artery Disease (CAD)</i> . . . . .	320
				<i>General Resources</i> . . . . .	320